MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · see citing works

Glutamine reliance in cell metabolism

Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021 · see citing works

A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells

Yoo, H. C., Park, S. J., Nam, M., Kang, J., Kim, K., Yeo, J. H., Kim, J.-K., Heo, Y., Lee, H. S., Lee, M. Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.020 · Cited by 449 · see citing works

Targeting hypoxic tumor microenvironment in pancreatic cancer

Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., Zhao, F., You, L., Zheng, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01030-w · Cited by 419 · see citing works

Cell death in pancreatic cancer: from pathogenesis to therapy

Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 339 · see citing works

A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy

Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 249 · see citing works

Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia

McDonald, P. C., Chafe, S. C., Brown, W. S., Saberi, S., Swayampakula, M., Venkateswaran, G., Nemirovsky, O., Gillespie, J. A., Karasinska, J. M., Kalloger, S. E., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.004 · Cited by 224 · see citing works

The roles of glucose metabolic reprogramming in chemo- and radio-resistance

Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 191 · see citing works

Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer

Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., Lucas, F. A. S., Fernandes, C. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126915 · Cited by 173 · see citing works

Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis

Zeng, Z., Zhao, Y. B., Chen, Q., Zhu, S., Niu, Y., Zeng, Y., Hu, P., Chen, D., Xu, P., Chen, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01960-w · Cited by 171 · see citing works

Metabolic reprogramming, sensing, and cancer therapy

Mao, Y., Xia, Z., Xia, W., & Jiang, P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115064 · Cited by 168 · see citing works

The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance

Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 151 · see citing works

O-GlcNAc Transferase Links Glucose Metabolism to MAVS-Mediated Antiviral Innate Immunity

Li, T., Li, X., Attri, K. S., Liu, C., Li, L., Herring, L. E., Asara, J. M., Lei, Y. L., Singh, P. K., Gao, C., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.11.001 · Cited by 146 · see citing works

Acquired resistance in cancer: towards targeted therapeutic strategies

Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 145 · see citing works

The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint

Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 133 · see citing works

Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma

Nie, M., Yao, K., Zhu, X., Chen, N., Xiao, N., Wang, Y., Peng, B., Yao, L., Li, P., Zhang, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26685-y · Cited by 126 · see citing works

Glucose Metabolism in Pancreatic Cancer

Liang, Y., Raj, P. S., Yao, W., & Ying, H. (2019) · Cancers · doi:10.3390/cancers11101460 · Cited by 122 · see citing works

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression

Wallez, Y., Dunlop, C. R., Johnson, T. I., Koh, S., Fornari, C., Yates, J. W. T., Fernández, S. B. D. Q., Lau, A., Richards, F. M., & Jodrell, D. I. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0010 · Cited by 110 · see citing works

MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome

Lucarelli, G. T., Rutigliano, M., Loizzo, D., di Meo, N. A., Lasorsa, F. M., Mastropasqua, M. G., Maiorano, E., Bizzoca, C., Vincenti, L., Battaglia, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213968 · Cited by 110 · see citing works

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

Nelson, J. K., Thin, M. Z., Evan, T., Howell, S. A., Wu, M., Almeida, B., Legrave, N. M., Koenis, D. S., Koifman, G., Sugimoto, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29684-9 · Cited by 104 · see citing works

Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance

Yamada, K. J., Heim, C. E., Xi, X., Attri, K. S., Wang, D., Zhang, W., Singh, P. K., Bronich, T. K., & Kielian, T. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008354 · Cited by 94 · see citing works

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 92 · see citing works

BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation

Li, Z., Ge, Y., Dong, J., Wang, H., Zhao, T., Wang, X., Liu, J., Gao, S., Shi, L., Yang, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.249 · Cited by 74 · see citing works

Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer

Serkova, N. J., Glunde, K., Haney, C. R., Farhoud, M., Lille, A. D., Redente, E. F., Simberg, D., Westerly, D., Griffin, L. R., & Mason, R. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0373 · Cited by 73 · see citing works

Signaling Pathways Regulating Redox Balance in Cancer Metabolism

Santis, M. C. D., Porporato, P. E., Martini, M., & Morandi, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00126 · Cited by 73 · see citing works

Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer

Zhang, J., Mao, S., Guo, Y., Wu, Y., Yao, X., & Huang, Y. (2019) · Bioscience Reports · doi:10.1042/bsr20181826 · Cited by 69 · see citing works

Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways

Yu, L., Wang, M., Yang, Y., Xu, F., Zhang, X., Xie, F., Gao, L., & Li, X. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008696 · Cited by 68 · see citing works

Transketolase Deficiency Protects the Liver from DNA Damage by Increasing Levels of Ribose 5-Phosphate and Nucleotides

Li, M., Lu, Y., Li, Y., Tong, L., Gu, X., Meng, J., Zhu, Y., Wu, L., Feng, M., Tian, N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3776 · Cited by 67 · see citing works

Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation

Zhang, J., Song, J., Tang, S., Zhao, Y., Wang, L., Luo, Y., Tang, J., Ji, Y., Wang, X., Li, T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112620 · Cited by 61 · see citing works

The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines

Li, M., Zhang, X., Lu, Y., Meng, S., Quan, H., Hou, P., Tong, P., Chai, D., Gao, X., Zheng, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2225-6 · Cited by 57 · see citing works

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer

Sun, Y. P., Ren, D., Zhou, Y., Shen, J., Wu, H., Jin, X., Fan, P., Gao, Y., Wu, H., & Jin, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04118-4 · Cited by 56 · see citing works

Associations between GLUT expression and SUV values derived from FDG-PET in different tumors—A systematic review and meta analysis

Meyer, H., Wienke, A., & Surov, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217781 · Cited by 56 · see citing works

Forming cytoophidia prolongs the half-life of CTP synthase

Sun, Z., & Liu, J. (2019) · Cell Discovery · doi:10.1038/s41421-019-0098-6 · Cited by 51 · see citing works

Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation

Ricciardiello, F., Yang, G., Palorini, R., Li, Q., Giampà, M., Zhao, F., You, L., Ferla, B. L., Vitto, H. D., Guan, W., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1260-1 · Cited by 47 · see citing works

MUC1: An emerging target in cancer treatment and diagnosis

Qing, L., Li, Q., & Dong, Z. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.08.001 · Cited by 45 · see citing works

Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00226-5 · Cited by 42 · see citing works

Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma

Zhang, L., Li, Y., Dai, Y., Wang, D., Wang, X., Cao, Y., Liu, W., & Tao, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-98381-2 · Cited by 38 · see citing works

Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

Ahmad, I. M., Dafferner, A. J., O’Connell, K. A., Mehla, K., Britigan, B. E., Hollingsworth, M. A., & Abdalla, M. Y. (2021) · Cancers · doi:10.3390/cancers13092264 · Cited by 36 · see citing works

Distinct roles for the hypoxia-inducible transcription factors HIF-1α and HIF-2α in human osteoclast formation and function

Knowles, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78003-z · Cited by 35 · see citing works

Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition

Shi, X., Wang, M., Zhang, Y., Guo, X., Liu, M., Zhou, Z., Zhao, Y., He, R., Gao, Y., Liu, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104352 · Cited by 34 · see citing works

Dysregulation of the miR-148a–GLUT1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma

Tiemin, P., Xiao, P., Qingfu, L., Wang, Y., Junlin, X., Zhefeng, H., Ming, Z., Desen, L., & Qinghui, M. (2020) · Oncogenesis · doi:10.1038/s41389-020-0207-2 · Cited by 32 · see citing works

Alterations of commensal microbiota are associated with pancreatic cancer

Chen, T., Li, X., Li, G., Liu, Y., Huang, X., Ma, W., Qian, C., Jie, G., Wang, S., Qin, Q., et al. (2023) · The International Journal of Biological Markers · doi:10.1177/03936155231166721 · Cited by 32 · see citing works

Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics

Smigiel, J. M., Parameswaran, N., & Jackson, M. W. (2018) · Cancers · doi:10.3390/cancers10010014 · Cited by 31 · see citing works

The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway

Han, L., Jiang, J., Ma, Q., Wu, Z., & Wang, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4363 · Cited by 31 · see citing works

Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy

Zhu, M. P., & Wang, S. (2021) · Small Science · doi:10.1002/smsc.202000056 · Cited by 31 · see citing works

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia

Gaidano, V., Houshmand, M., Vitale, N., Carrà, G., Morotti, A., Tenace, V., Rapelli, S., Sainas, S., Pippione, A. C., Giorgis, M., et al. (2021) · Cancers · doi:10.3390/cancers13051003 · Cited by 31 · see citing works

Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions

Strapcova, S., Takáčová, M., Csáderová, L., Martinelli, P., Lukáčiková, Ľ., Gál, V., Kopáček, J., & Švastová, E. (2020) · Cancers · doi:10.3390/cancers12082005 · Cited by 30 · see citing works

Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells

Santos-Jiménez, J. D. L., Campos-Sandoval, J. A., Márquez-Torres, C., Urbano-Polo, N., Brøndegaard, D., Martín‐Rufián, M., Lobo, C., Peñalver, A., Gómez-García, M. C., Martín-Campos, J., et al. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00712-y · Cited by 28 · see citing works

Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality

Baird, L., Kensler, T. W., & Yamamoto, M. P. (2022) · IUBMB Life · doi:10.1002/iub.2680 · Cited by 26 · see citing works

MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways

Yang, S. S., Tang, W., Azizian, A., Gaedcke, J., Ohara, Y., Cawley, H., Hanna, N. N., Ghadimi, M. B., Lal, T., Sen, S., et al. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae025 · Cited by 25 · see citing works

MiR-205 mediated APC regulation contributes to pancreatic cancer cell proliferation

Qin, R.-F., Zhang, J., Huo, H., Yuan, Z.-J., & Xue, J.-D. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i28.3775 · Cited by 23 · see citing works

Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α

Yoneda, A., Minomi, K., & Tamura, Y. (2021) · Cancer Science · doi:10.1111/cas.14976 · Cited by 23 · see citing works

Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling

Mesmar, F., Dai, B., Ibrahim, A. A., Hases, L., Jafferali, M. H., Augustine, J. J., DiLorenzo, S., Kang, Y., Zhao, Y., Wang, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2581 · Cited by 21 · see citing works

Methotrexate-based PROTACs as DHFR-specific chemical probes

Rana, S., Dranchak, P. K., Dahlin, J. L., Lamy, L., Li, W., Oliphant, E. N., Shrimp, J. H., Rajacharya, G. H., Tharakan, R., Holland, D. O., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.014 · Cited by 20 · see citing works

Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

Yada, E., Kasajima, R., Niida, A., Imoto, S., Miyano, S., Miyagi, Y., Sasada, T., & Wada, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101396 · Cited by 20 · see citing works

Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies

du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 19 · see citing works

An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies

Hasselluhn, M. C., Schlösser, D., Versemann, L., Schmídt, G., Ulisse, M., Oschwald, J., Zhang, Z., Hamdan, F. H., Xiao, H., Kopp, W., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.10.026 · Cited by 19 · see citing works

Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy

Bhoopathi, P., Mannangatti, P., Das, S. K., Fisher, P. B., & Emdad, L. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.010 · Cited by 18 · see citing works

Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics

Won, E.-J., Park, H., Yoon, T., & Cho, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010137 · Cited by 17 · see citing works

Hypoxia‐mediated attenuation of EGLN2 inhibition of the NF‐κB signaling pathway leads to the formation of a loop between HIF‐1α and MUC1‐C promoting chemoresistance in bladder cancer

Qing, L., Li, Q., Yang, Y., Xu, W., Wang, Y., Li, R., You, C., & Dong, Z. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23725 · Cited by 17 · see citing works

Bitter melon juice-intake modulates glucose metabolism and lactate efflux in tumors in its efficacy against pancreatic cancer

Dhar, D., Raina, K., Kant, R., Wempe, M. F., Serkova, N. J., Agarwal, C., & Agarwal, R. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz114 · Cited by 16 · see citing works

A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research

Qing, L., Li, Q., Yang, Y., Xu, W., & Dong, Z. (2022) · BMC Urology · doi:10.1186/s12894-022-01067-8 · Cited by 14 · see citing works

MUC1 confers radioresistance in head and neck squamous cell carcinoma (HNSCC) cells

Huang, T., Bi, Y., Cui, Z., Guan, J., & Huang, Y. (2020) · Bioengineered · doi:10.1080/21655979.2020.1791590 · Cited by 14 · see citing works

MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer

Fu, X., Tang, N., Xie, W., Mao, L., & Qiu, Y. (2020) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(20)30019-4 · Cited by 14 · see citing works

Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment

Zhang, J., Wang, Y., Wang, L., You, L., & Zhang, T. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002758 · Cited by 13 · see citing works

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer

Moreno, P., Ohara, Y., Craig, A. J., Liu, H., Yang, S. S., Dorsey, T. H., Zhang, L., Panigrahi, G., Cawley, H., Azizian, A., et al. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae056 · Cited by 11 · see citing works

Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer

Phan, T. X., Nguyen, V. H., Buettner, R., Morales, C. J., Yang, L., Wong, P., Tsai, W., Salazar, M. D., Gil, Z., Diamond, D. J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60473 · Cited by 10 · see citing works

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma

Ali, A. H., Chianese, U., Papulino, C., Toraldo, A., Abakar, M. E. A., Passaro, E., Cennamo, R., Gaudio, N. D., Altucci, L., & Benedetti, R. (2022) · Cancers · doi:10.3390/cancers14153799 · Cited by 10 · see citing works

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth

Soliman, G. A., Shukla, S. K., Etekpo, A., Gunda, V., Steenson, S., Gautam, N., Alnouti, Y., & Singh, P. K. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa131 · Cited by 8 · see citing works

Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient‐derived xenograft tumors

Dhar, D., Raina, K., Kumar, D., Wempe, M. F., Bagby, S. M., Pitts, T. M., Orlicky, D. J., Agarwal, C., Messersmith, W. A., & Agarwal, R. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23251 · Cited by 8 · see citing works

Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer

Shen, X., Chen, Y., Liu, M., Shi, J., Tang, Y., Yang, X., Xu, D., Yao, H., Lu, P., Sun, Y., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.05.047 · Cited by 8 · see citing works

HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling

Formica, V., Riondino, S., Morelli, C., Guerriero, S., D’Amore, F., Grazia, A. D., Blanco, G. D. V., Sica, G. S., Arkenau, H., Monteleone, G., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02266-2 · Cited by 7 · see citing works

Important roles of Hif1a in maternal or adult BPA exposure induced pancreatic injuries

Liu, H., Zhou, Y., Li, Y., & Gong, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-38614-8 · Cited by 7 · see citing works

ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer

Li, Y., Wang, H., Chen, L., Gong, Y., Zheng, D., Li, F., Wu, C., He, Z., & Yu, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08061-6 · Cited by 6 · see citing works

Prolactin receptor potentiates chemotherapy through miRNAs ‐induced G6PD / TKT inhibition in pancreatic cancer

Liao, Y., Huang, P.-Q., Pan, H., Gai, Y., Zhan, Y., Li, S., & Nie, H. (2024) · The FASEB Journal · doi:10.1096/fj.202302287rr · Cited by 5 · see citing works

Classification From Compressive Representations Of Data

Coppa, B., David, D., Héliot, R., & Michel, O. (2012) · HAL · doi:10.5281/zenodo.43132 · Cited by 4 · see citing works

IDH1 Reprograms Nucleotide Metabolism by Inducing Chromatin Remodeling and DHODH Transcription to Drive Chemoresistance in Nasopharyngeal Carcinoma

Zhao, Y., Ou, C., Huang, H., Wang, Y., Shen, J., Li, Y., He, Q., Han, Z., Xie, Y., Zhong, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-2313 · Cited by 3 · see citing works

Mucin 1 promotes salivary gland cancer cell proliferation and metastasis by regulating the epidermal growth factor receptor signaling pathway

Lü, H., Xu, W., Wu, Y., Yang, W.-J., & Liu, S. (2023) · Journal of Dental Sciences · doi:10.1016/j.jds.2023.01.035 · Cited by 3 · see citing works

Robust Validation and Comprehensive Analysis of a Novel Signature Derived from Crucial Metabolic Pathways of Pancreatic Ductal Adenocarcinoma

Gu, W., Mo, S., Wang, Y., Kawabata‐Iwakawa, R., Zhang, W., Yang, Z., Sun, C., Tsushima, Y., Xu, H., & Nakajima, T. (2022) · Cancers · doi:10.3390/cancers14071825 · Cited by 3 · see citing works

Use of oral squamous cell carcinoma: A discussion paper

Senevirathna, K., Jayawardana, N. U., Gamage, C. U., Perera, A. G. U., Jayasinghe, R. D., & Seneviratne, B. (2023) · International Health Trends and Perspectives · doi:10.32920/ihtp.v3i1.1676 · Cited by 3 · see citing works

Genome profiling of mismatch repair genes in eight types of tumors

Wang, S., Guan, G., Zou, C., Guo, Q., Cheng, W., Shen, S., Fang, D., Wu, A., Li, G., & Zhu, C. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1922160 · Cited by 2 · see citing works

Systemic Metabolomic Changes Associated with Chemotherapy: Role in Personalized Therapy

Kalita, B., Barik, G. K., Sharma, T., Taunk, K., Bhavsar, P. P., Santra, M. K., & Rapole, S. (2022) · Wiley eBooks · doi:10.1002/9781119851042.ch24 · Cited by 2 · see citing works

Combination Therapies for the Management of Cancer Immunotherapy

Chenchula, S., Anitha, K., Posinasetty, B., Bhatt, S., Mishra, N., Sharma, N., & Chandran, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_5 · Cited by 1 · see citing works

Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer

Li, X., Liu, L., Luo, L., Deng, M., Jiang, Y., Ren, W., & Qian, H. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113185 · Cited by 1 · see citing works

Overcoming multifaceted challenges in cancer treatment: Targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy

Ansari, A. M., Sharma, N. K., Tripathi, K., Bhardwaj, G., Chauhan, R., Tonk, R. K., Shahwan, M. J., Tuli, H. S., & Chauhan, A. P. S. (2025) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2025.204012 · Cited by 1 · see citing works

Tumor metabolic reprogramming in therapeutic resistance

Siegel, P. M., & Ursini‐Siegel, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00005-x

Management of Primary Pancreatic Cancer

Pitiyarachchi, O., Kokkinos, J., Sharbeen, G., Phillips, P. A., Gandy, R. C., Haghighi, K. S., Moses, D. A., Thompson, S. R., Borbasi, J., Strutt, R., et al. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch20

Up-Regulation of Non-Homologous End-Joining by MUC1

Bessho, T. (2024) · Genes · doi:10.3390/genes15060808

Additional file 8 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986352

Additional file 3 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986337

Additional file 1 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986331

Additional file 2 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986334

Additional file 7 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986349

Additional file 9 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986355

Additional file 5 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986343

Additional file 6 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986346

Additional file 4 of Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Sharma, N., Bhushan, A., He, J., Kaushal, G., & Bhardwaj, V. (2020) · Figshare · doi:10.6084/m9.figshare.12986340

Mechanisms of Gemcitabine Resistance in Pancreatic Cancer

章, 靓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162492

Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer

Cai, K., Chen, S., Ma, G., Wu, W., Wang, S., Quan, B., Jin, C., Wang, Y., He, Z., & Wang, T. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08958-w

Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma

Ouyang, W., Wang, J., Chen, J., Fang, Z., Wei, T., Qian, J., & Gui, S. (2026) · Translational research · doi:10.1016/j.trsl.2026.09.009

The reciprocal loop of MALAT1 and HIF-1α facilitates gemcitabine resistance in pancreatic cancer by enhancing glycolysisPreprint

Zhang, Z., Zhao, H., Yang, W., Zhao, C., Tang, Z., Mei, P., Gong, Q., & Tao, J. (2021) · Research Square · doi:10.21203/rs.3.rs-135235/v2

LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway

Xu, F., Huang, M., Chen, Q., Niu, Y., Hu, Y., Hu, P., Chen, D., He, C., Huang, K., Zeng, Z., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0281 · Cited by 134 · see citing works

MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer

Dang, C. V. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.006 · Cited by 5 · see citing works

Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer

Kasuya, K. (2011) · Oncology Reports · doi:10.3892/or.2011.1457 · Cited by 39 · see citing works

Abstract 5391: MUC1 and HIF-1α signaling interactions modulate glucose flux in pancreatic cancer.

Purohit, V., Chaika, N. V., Gebregiworgis, T., Radhakrishnan, P., Zhang, B., Mehla, K., Yu, F., Johnson, K. R., Powers, R., Hollingsworth, M. A., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5391